A weekly podcast for physicians interested in evidence based medicine and rheumatology. Find the papers at ebrheum.com
Episodes
Tuesday Apr 14, 2020
Tuesday Apr 14, 2020
Back this week to update you on the data for hydroxychlorquine. There has been a lot of action - and very little resolution - to this issue since my last episode. Let me know what you think, follow along on twitter @ebrheum and get the papers themselves at ebrheum.com.
Thursday Apr 02, 2020
Thursday Apr 02, 2020
Diving into a new "rheum treatments for COVID" topic today - IL6 inhibition. It took me awhile to get to this, in part because the hydroxychloroquine situation has been something to behold and in part because there's just nothing to say. I cover two case series here, neither of which are strong evidence. Hope you enjoy! Follow me @ebrheum to let me know what you think!
Wednesday Mar 25, 2020
Wednesday Mar 25, 2020
Trying to get to IL6, but so much happening in the world of hydroxychloroquine. As I said at the beginning, things are likely to move fast. I'm planning to make this as an extended series, so please go back and listen to #1 before you listen to this! This episode will round out the paper by Gautret et al. and discuss the best copy of a paper by Jun et al. that I've been able to find. Follow me @ebrheum and share with friends!
Thursday Mar 19, 2020
Thursday Mar 19, 2020
Welcome to the first episode of my series on immunosuppressive treatments for COVID-19. Today I cover the Renault trial and a nice systematic review, which I believe are the two best options in the published literature to date. Find the papers and ways to subscribe at ebrheum.com and follow me on twitter @ebrheum
Thursday Mar 19, 2020
Thursday Mar 19, 2020
Quick update podcast. I'm planning to tweak the format of my podcast to better respond to COVID-19. I'll be doing more or less the same thing but with a different structure and focus. It seems a little peculiar to discuss anything else during the current crisis, so I intend to refocus and hope to offer value to listeners. Share with friends - ebrheum.com and @ebrheum
Wednesday Feb 19, 2020
Wednesday Feb 19, 2020
PEXIVAS has landed! This week I go over the trial and my take on it's results. Impressive undertaking that answered two questions for a subset of patients with AAV - well worth the time to kick back and read the trial in full. Let me know what you think about the podcast @ebrheum!
Thursday Feb 06, 2020
Thursday Feb 06, 2020
(Yet) another RCT this week! Nice investigator initiated trial with many wonderful strengths and a few crippling flaws. Great opportunity to think about a common problem in practice as well as a separate common problem in trials!
Thursday Jan 23, 2020
Thursday Jan 23, 2020
This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE. Great to see a new drug in this disease state; interesting to think through how these trials played out. Get the papers and the pod at ebrheum.com and follow me @ebrheum if you'd like to share feedback!
Thursday Jan 16, 2020
Thursday Jan 16, 2020
Happy New Year! This week Dr. Anisha Dua (@anisha_dua) and Dr. Sarah Fantus (@sarahfantus) debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line." Please be sure to VOTE AGAIN on twitter (@ebrheum) after you have listened!
Thursday Dec 19, 2019
Thursday Dec 19, 2019
This week I go back to a topic from episode 42, the SENSCIS trial and nintedanib for SSc-ILD. The way this medication has been received and a recent article I wrote for The Rheumatologist gave me a nice jumping off point to cover a few more issues from this. Be sure to follow me @EBRheum to let me know what you think! The corresponding article is available here: https://www.the-rheumatologist.org/article/fda-approves-nintedanib-for-ssc-ild-but-temper-your-expectations/